Zaharko D S, Covey J M
Cancer Treat Rep. 1984 Oct;68(10):1255-64.
The purpose of these studies was to investigate the potential modulation by thymidine in vivo of the antitumor action of 5-aza-2'-deoxycytidine (DAC). During the course of these investigations it was observed that DAC given as a single dose to mice bearing late L1210 tumor resulted in cell kills estimated to be close to 6 logs. Because of the potentially large antigen load released by such a cell kill, the immune modulator pyran copolymer was also tested in combination with DAC. Thymidine increased the cytotoxicity of DAC but not in a selective fashion. Doses of DAC in combination with thymidine were more toxic to host mice than equivalent doses of DAC alone, but no therapeutic benefit was apparent with this combination at maximally tolerated doses. A single dose of pyran copolymer and DAC appears to result in an adjuvant action that eliminates the few remaining L1210 cells refractory to DAC chemotherapy. Doses of DAC alone that result in lengthy increases in survival times but no cures resulted in a substantial number of cures when used in combination with pyran copolymer.
这些研究的目的是调查胸苷在体内对5-氮杂-2'-脱氧胞苷(DAC)抗肿瘤作用的潜在调节作用。在这些研究过程中,观察到给携带晚期L1210肿瘤的小鼠单次注射DAC可导致估计接近6个对数的细胞杀伤。由于这种细胞杀伤可能释放大量抗原,免疫调节剂聚吡喃共聚物也与DAC联合进行了测试。胸苷增加了DAC的细胞毒性,但并非以选择性方式。与单独使用等效剂量的DAC相比,DAC与胸苷联合使用的剂量对宿主小鼠毒性更大,但在最大耐受剂量下这种联合用药并未显示出治疗益处。单次注射聚吡喃共聚物和DAC似乎会产生佐剂作用,消除对DAC化疗耐药的少数残留L1210细胞。单独使用导致存活时间延长但无法治愈的DAC剂量,与聚吡喃共聚物联合使用时可导致大量治愈。